Results 51 to 60 of about 589 (105)

Efficacy and safety of eltrombopag in the treatment of severe chronic immune thrombocytopenia in children of China: A single-center observational study

International Journal of Immunopathology and Pharmacology, 2019
The treatment of severe chronic immune thrombocytopenia (SCITP) in pediatric patients is challenging. We evaluated the clinical efficacy and safety of eltrombopag in children with SCITP in China. This observational study was carried out at the Hematology
Xiaoling Cheng, Kuo Yan, Jingyao Ma, Zhenping Chen, Libo Zhao, Xiaoling Wang, Runhui Wu   +6 more
doaj   +1 more source

Refractory autoimmune hemolytic anemia with poor erythropoietic compensation in combined immunodeficiency: A case series

Pediatric Allergy and Immunology, Volume 37, Issue 8, August 2026.
Letizia Baldini, Mattia Moratti, Alessandro Ruggi, Francesco Licciardi, Fraia Melchionda, Maura Fois, Maria Elena Cantarini, Elena Facchini, Veronica Barat, Giovanni Del Borrello, Bruno Fattizzo, Elena Sabattini, Clara Bertuzzi, Riccardo Masetti, Francesca Conti   +14 more
wiley   +1 more source

Host–Pathogen Dual Targeting With Repurposed Drugs Identifies a Synergistic Therapy for Intracellular Staphylococcus aureus

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
A large intracellular drug‐repurposing screen identifies a potent synergy between 5‐fluoro‐2′‐deoxycytidine and rifapentine, acting through dual host–pathogen targeting to reduce Staphylococcus aureus burdens across strains, cell types, and infection models (created with BioRender).
Blanca Lorente‐Torres, Helena Á. Ferrero, Pablo Castañera, Jesús Llano‐Verdeja, Sergio Fernández‐Martínez, Amanda Herrero‐González, Farzaneh Javadimarand, Roberto López, Jesús F. Aparicio, Andrew M. Edwards, Volker Behrends, Luis M. Mateos, Álvaro Mourenza, Michal Letek   +13 more
wiley   +1 more source

This Is Not a Myeloproliferative Neoplasm…

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
Stephanie Juané Kennedy
wiley   +1 more source

The Role of N6‐Methyladenosine Modification in Health and Disease

MedComm, Volume 7, Issue 6, June 2026.
N6‐methyladenosine (m6A) is the most prevalent internal RNA modification in eukaryotes, acting as a pivotal epitranscriptomic regulator of RNA metabolism. This modification plays a dual role: it maintains physiological homeostasis under normal conditions but drives disease progression when dysregulated.
Linghuan Li, Yuanhai Sun, Wanfang Zheng, Lingqin Li, Yaqian Feng, Minyou Qi, Hanbing Li   +6 more
wiley   +1 more source

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia

Haematologica, 2018
Few therapeutic options are available for patients with aplastic anemia who are ineligible for transplantation or refractory to immunosuppressive therapy. Eltrombopag was recently shown to produce trilineage responses in refractory patients. However, the
Etienne Lengline, Bernard Drenou, Pierre Peterlin, Olivier Tournilhac, Julie Abraham, Ana Berceanu, Brigitte Dupriez, Gaelle Guillerm, Emmanuel Raffoux, Flore Sicre de Fontbrune, Lionel Ades, Marie Balsat, Driss Chaoui, Paul Coppo, Selim Corm, Thierry Leblanc, Natacha Maillard, Louis Terriou, Gerard Socié, Regis Peffault de Latour   +19 more
doaj   +1 more source

Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation

Therapeutic Advances in Hematology, 2020
Background: Patients with post-transplant cytopenias due to poor graft function or primary engraftment failure show poor prognosis with a high mortality rate mainly because of graft versus host disease (GVHD), infection and/or bleeding. Treatment options
Semra Aydin, Chiara Dellacasa, Sara Manetta, Luisa Giaccone, Laura Godio, Giorgia Iovino, Benedetto Bruno, Alessandro Busca   +7 more
doaj   +1 more source

Review article: THE ROLE OF ELTROMBOPAG AND ROMIPLOSTIM AS THE THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): WHAT IS TPO-RA, WHEN TPO-RA IS USED AND HOW TO TAKE TPO-RA?

Folia Medica Indonesiana, 2016
Idiopathic thrombocytopenic purpura is a autoimmune disease characterized thrombocytopenia casued by excessive platelet destruction. However, both platelet destruction and reduced thrombopoietin level are occurred in some cases. Therefore, new management
Jefri Pratama Susanto
doaj   +1 more source

Eltrombopag-Induced Cerebral Venous Thrombosis: A Case Report and Literature Review

Case Reports in Hematology
Immune thrombocytopenia purpura (ITP) is initially treated with steroids, but TPO-RAs such as eltrombopag are used for chronic cases. Though effective, eltrombopag has been linked to thromboembolic events, with cerebral venous thrombosis (CVT) being a ...
I-Wei Lin, Ken-Hong Lim, Yen-Chang Huang, Meng-Ta Sung   +3 more
doaj   +1 more source

Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)Research in context

EClinicalMedicine
Summary: Background: Recombinant human thrombopoietin (rhTPO) at a fixed dose of 300 U/kg/day for 2 weeks has demonstrated good efficacy and safety in adults with immune thrombocytopenia (ITP).
Yunfei Chen, Ting Sun, Da Gao, Wei Wang, Zeping Zhou, Guangxun Gao, Yi Wang, Hu Zhou, Yanping Song, Yinghui Lai, Zhenyu Yan, Jinsong Yan, Jie Bai, Lei Zhang   +13 more
doaj   +1 more source